Immunitas Therapeutics Announces Appointment of James Wooldridge as Chief Medical Officer and Upcoming Presentation at ASH 2023 Annual Meeting December 5, 2023
Immunitas Therapeutics Presents Preclinical Data Demonstrating Potential of Novel Cancer Immunotherapy IMT-009 at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting November 15, 2022
Immunitas Therapeutics Receives FDA Clearance of IND Application for IMT-009 in Solid Tumors and Hematological Malignancies September 23, 2022
Out to prove the next big I/O target, Immunitas’ chief dealmaker steps up to CEO role November 16, 2021
